AGING CELL:抑癌基因PTEN如何介导长寿?

2019-02-18 海北 MedSci原创

含PDZ结构域的蛋白质(PDZ蛋白质)可以作为蛋白质-蛋白质相互作用的支架,并且对于各种信号转导过程是至关重要的。然而至今为止,关于PDZ蛋白在机体寿命和衰老中的作用我们仍然知之甚少。

含PDZ结构域的蛋白质(PDZ蛋白质)可以作为蛋白质-蛋白质相互作用的支架,并且对于各种信号转导过程是至关重要的。然而至今为止,关于PDZ蛋白在机体寿命和衰老中的作用我们仍然知之甚少。

最近,研究人员证明了KIN-4,一种含有PDZ结构域的微管相关丝氨酸 - 苏氨酸(MAST)蛋白激酶,是通过结合秀丽隐杆线虫中的PTEN磷酸酶起作用的关键长寿因子。

通过针对PDZ蛋白的靶向遗传筛选,研究人员发现,kin-4是daf-2 /胰岛素/ IGF-1受体突变体的寿命增长所必需的。然后,研究人员还证明神经元是kin-4长寿促进作用的关键组织。

研究人员发现KIN-4的PDZ结构域结合PTEN,这是daf-2突变体寿命延长的关键因素。此外,KIN-4和PTEN之间的相互作用对于延长daf-2突变体的寿命至关重要。

由于秀丽隐杆线虫的寿命调节的许多方面在进化上是保守的,因此MAST家族激酶也可能通过与PTEN的相互作用来调节哺乳动物的衰老和/或年龄相关疾病。


原始出处:

Seon Woo A. An et al. KIN‐4/MAST kinase promotes PTEN‐mediated longevity of Caenorhabditis elegans via binding through a PDZ domain. Aging Cell, 2019; doi: https://doi.org/10.1111/acel.12906


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1640666, encodeId=6a9b164066674, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Fri Apr 26 00:36:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961437, encodeId=630c196143e60, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Mar 06 06:36:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871160, encodeId=7bae18e116065, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 30 09:36:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315931, encodeId=35b0131593160, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Feb 20 09:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323249, encodeId=b29b13232491a, content=<a href='/topic/show?id=9934549500e' target=_blank style='color:#2F92EE;'>#抑癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54950, encryptionId=9934549500e, topicName=抑癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Wed Feb 20 09:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373940, encodeId=01d213e39402f, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Wed Feb 20 09:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1640666, encodeId=6a9b164066674, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Fri Apr 26 00:36:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961437, encodeId=630c196143e60, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Mar 06 06:36:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871160, encodeId=7bae18e116065, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 30 09:36:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315931, encodeId=35b0131593160, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Feb 20 09:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323249, encodeId=b29b13232491a, content=<a href='/topic/show?id=9934549500e' target=_blank style='color:#2F92EE;'>#抑癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54950, encryptionId=9934549500e, topicName=抑癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Wed Feb 20 09:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373940, encodeId=01d213e39402f, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Wed Feb 20 09:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2019-03-06 zhouqu_8
  3. [GetPortalCommentsPageByObjectIdResponse(id=1640666, encodeId=6a9b164066674, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Fri Apr 26 00:36:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961437, encodeId=630c196143e60, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Mar 06 06:36:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871160, encodeId=7bae18e116065, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 30 09:36:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315931, encodeId=35b0131593160, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Feb 20 09:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323249, encodeId=b29b13232491a, content=<a href='/topic/show?id=9934549500e' target=_blank style='color:#2F92EE;'>#抑癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54950, encryptionId=9934549500e, topicName=抑癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Wed Feb 20 09:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373940, encodeId=01d213e39402f, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Wed Feb 20 09:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1640666, encodeId=6a9b164066674, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Fri Apr 26 00:36:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961437, encodeId=630c196143e60, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Mar 06 06:36:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871160, encodeId=7bae18e116065, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 30 09:36:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315931, encodeId=35b0131593160, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Feb 20 09:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323249, encodeId=b29b13232491a, content=<a href='/topic/show?id=9934549500e' target=_blank style='color:#2F92EE;'>#抑癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54950, encryptionId=9934549500e, topicName=抑癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Wed Feb 20 09:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373940, encodeId=01d213e39402f, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Wed Feb 20 09:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2019-02-20 xiaogang317
  5. [GetPortalCommentsPageByObjectIdResponse(id=1640666, encodeId=6a9b164066674, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Fri Apr 26 00:36:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961437, encodeId=630c196143e60, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Mar 06 06:36:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871160, encodeId=7bae18e116065, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 30 09:36:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315931, encodeId=35b0131593160, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Feb 20 09:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323249, encodeId=b29b13232491a, content=<a href='/topic/show?id=9934549500e' target=_blank style='color:#2F92EE;'>#抑癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54950, encryptionId=9934549500e, topicName=抑癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Wed Feb 20 09:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373940, encodeId=01d213e39402f, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Wed Feb 20 09:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1640666, encodeId=6a9b164066674, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Fri Apr 26 00:36:00 CST 2019, time=2019-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961437, encodeId=630c196143e60, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Mar 06 06:36:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871160, encodeId=7bae18e116065, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jun 30 09:36:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315931, encodeId=35b0131593160, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Feb 20 09:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323249, encodeId=b29b13232491a, content=<a href='/topic/show?id=9934549500e' target=_blank style='color:#2F92EE;'>#抑癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54950, encryptionId=9934549500e, topicName=抑癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Wed Feb 20 09:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373940, encodeId=01d213e39402f, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Wed Feb 20 09:36:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]

相关资讯

Eur Rev Med Pharmacol Sci:研究发现miR-374b可以通过降解PTEN促进MSCs的成骨分化

本研究旨在探究miR-374b是否通过介导PTEN促进MSCs分化为成骨细胞,从而促进骨折愈合。 提取小鼠间充质干细胞进行实验。流式细胞术确定MSCs表面抗原的表达以鉴定其纯度。使用茜素红染色来检测MSCs是否可以分化为成骨细胞。QRT-PCR检测骨折小鼠模型骨髓MSCs中成骨标志物基因的表达以及miR-374b和PTEN的表达。ALP活性检测试剂盒用于检测细胞中的ALP活性。 Western印迹

Oncol Lett:miR-26a-5p表达增强能够通过靶向PTEN促进膀胱癌的发展

最近,有研究人员评估了miR-26a-5p在膀胱癌(BC)发展过程中的表达和特异性角色。研究人员利用RT-PCR技术评估了miR-26a-5p在BC中和健康对照中的表达水平。研究发现,miR-26a-5p的表达在BC患者中显著增加。进一步的是,BC组织与临近的非瘤组织-26a-5p相比,miR-26a-5p表现出了更高的表达水平。在Ta-T1阶段,与BC患者喜爱那个比,miR-26a-5p的表达水

CLIN CANCER RES:PTEN表达与接受依维莫司治疗的肾细胞癌患者预后有关

PI3K / mTOR通路关键组分的基因组可以作为肾细胞癌(RCC)rapalog疗法的预测标志物。CLIN CANCER RES近期发表了一篇文章,在依维莫司与舒尼替尼对比的随机II期试验中验证这一假设。

Prostate Cancer P D:约翰·霍普金斯积极监控群体PTEN状态评估

格林森评分6(GS6)前列腺癌男性中,那些最初通过积极监控(AS)来进行治疗的多达一半的患者都需要确定性的治疗,通常是由于跟踪调查期间肿瘤等级的重新界定。最近,有研究人员调查了患有GS6癌症且进行AS的男性患者,活检时的PTEN状态和随后的临床病理结果。研究人员在约翰·霍普金斯AS群体中进行了案例-对照研究,这些患者诊断的活检组织可以用于免疫组化(IHC)染色,并在所有的患者中,利用遗传学确定的方

J Clin Invest:研究发现协同致死PTEN缺失前列腺肿瘤的表观遗传基因

综上所述,该研究阐明了PTEN和BRG1在肿瘤中发挥协同致死作用;靶向BRG1可以作为潜在治疗PTEN缺失前列腺肿瘤的手段。该项研究得到来自科技部国家重点研发计划、国家自然科学基金、中科院等的科研项目资助,同时也得到上海营养与健康院公共技术平台以及动物平台的支持。

Sci Signal:抑制脓血症引发炎症反应的分子机制

脓血症(sepsis)引发的全身炎症反应综合症(systemic inflammatory response syndrome, SIRS)是导致器官损伤和患者死亡的首要原因。